Tirzepatide for Weight Loss

Tirzepatide is a prescription medication used for weight loss and metabolic health. It is the first in a new class of dual-hormone medications, targeting both GLP-1 and GIP receptors simultaneously. It is the active ingredient in Zepbound (FDA-approved for chronic weight management) and Mounjaro (FDA-approved for type 2 diabetes), and is also available as a compounded formulation. In clinical trials, tirzepatide produced average weight loss of approximately 20–21% of body weight at the highest dose, the highest efficacy ever seen in a non-surgical weight loss intervention.

Tirzepatide activates two separate hormone receptor systems, GLP-1 and GIP, at the same time. GLP-1 receptor activation reduces appetite by signaling fullness to the brain, slows gastric emptying so you feel satisfied longer, and helps regulate blood sugar. GIP receptor activation adds a second layer of metabolic effect, influencing fat storage, energy expenditure, and insulin sensitivity. Together, these two pathways produce stronger and more comprehensive weight loss results than GLP-1 receptor activation alone.

Tirzepatide is sometimes referred to as a GLP-1 medication, but that description is only partially accurate. It is more precisely classified as a dual GLP-1 and GIP receptor agonist. Like semaglutide and other GLP-1 medications, it activates GLP-1 receptors, but it also activates GIP receptors, which GLP-1-only medications do not. This dual-receptor action is what makes tirzepatide a distinct class of medication with a broader metabolic effect profile.

Both semaglutide and tirzepatide are injectable weight loss medications that work by activating GLP-1 receptors, but tirzepatide goes a step further by also activating GIP receptors, making it a dual-hormone medication. This additional receptor action produces a broader metabolic effect and, on average, greater weight loss. Clinical trials show tirzepatide achieving approximately 20–21% average body weight reduction at the highest dose, compared to approximately 15% for semaglutide. That said, the best choice depends on your individual health profile, medical history, response to treatment, and cost considerations, not just efficacy averages. Your TOM physician will help you evaluate both options.

Tirzepatide has been evaluated in large-scale clinical trials and has received FDA approval for both weight management (Zepbound) and type 2 diabetes (Mounjaro). It has a well-documented safety profile. As with any prescription medication, tirzepatide carries risks and is not appropriate for every patient, including those with a personal or family history of certain thyroid cancers, Multiple Endocrine Neoplasia syndrome type 2, or a history of pancreatitis. This is why physician evaluation before prescribing and ongoing monitoring throughout treatment are essential parts of the TOM Weight Loss approach to care.

Some patients do experience temporary hair thinning during or following significant weight loss on tirzepatide. This is called telogen effluvium, a well-known response to rapid changes in caloric intake and body weight, and is not unique to tirzepatide. It is generally temporary and tends to resolve within a few months as the body stabilizes at a new weight. Ensuring sufficient protein intake throughout treatment can help minimize the effect. If you experience noticeable hair thinning, discuss it with your TOM physician so it can be monitored and addressed as part of your care plan.

Fatigue is reported by some patients, particularly in the early weeks of treatment or after dose increases. It is usually temporary. The most likely cause is reduced caloric intake as appetite decreases, your body may need a few weeks to adjust its energy systems to lower food intake. For most patients, energy levels stabilize and often improve over time as weight loss progresses and metabolic health improves. If fatigue is significant or persistent, your TOM physician may recommend slowing your dose escalation or making other adjustments.

Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro, prepared by a licensed compounding pharmacy. It is generally more cost-accessible than brand-name options and follows the same physician-supervised dosing approach. The key difference is regulatory status: Zepbound and Mounjaro are FDA-approved finished drug products, while compounded tirzepatide is not FDA-approved as a finished drug, it is regulated as a compounded preparation. Your TOM physician will help you evaluate which option makes the most sense given your access needs, insurance situation, and health profile.